source
- MapLight's schizophrenia drug fails primary endpoint in Phase 2, sending stock down over 60%MapLight Therapeutics saw its shares tumble more than 60% after a mid‑stage trial showed that its once‑daily schizophrenia candidate did not meet the primary efficacy endpoint, even though the over…
- Schrödinger launches AI agent Bunsen, CEO admits earlier AI skepticism was wrongSchrödinger announced the debut of its new AI agent, Bunsen, which is built on the company’s physics‑based software platform. The tool is intended to help biopharma researchers model molecular beha…